Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Whitehawk Therapeutics, Inc. has announced a significant private investment in public equity (PIPE) financing, expected to yield approximately $87.5 million. The transaction, which is set to close on May 14, 2026, involves the sale of 4,330,866 shares of common stock at a price of $3.92 per share. Additionally, the financing includes pre-funded warrants for the purchase of 17,991,021 shares at a price of $3.9199 per warrant, with an exercise price of $0.0001 per share. This funding round features participation from a group of institutional investors, including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, and Invus.

Whitehawk Therapeutics is a clinical-stage company focused on oncology therapeutics, leveraging advanced technologies to enhance antibody drug conjugate (ADC) cancer treatments. The firm aims to address the limitations of existing therapies by developing a three-asset ADC portfolio, which is exclusively licensed from WuXi Biologics. The proceeds from this PIPE financing will be utilized for working capital and general corporate purposes, with a primary focus on advancing its ADC pipeline and related development activities.

The oncology therapeutics sector is experiencing robust growth, driven by an increasing prevalence of cancer and a rising demand for innovative treatment options. Companies in this space are under pressure to deliver effective therapies that can improve patient outcomes, and Whitehawk’s focus on ADCs positions it well within this competitive landscape. The funding will help the company extend its cash runway into the second half of 2028, allowing it to continue its research and development efforts without interruption.

The participation of established institutional investors in this financing round underscores the confidence in Whitehawk's strategic direction and its potential to deliver meaningful advancements in cancer treatment. As the oncology sector continues to evolve, companies like Whitehawk are pivotal in driving innovation and addressing unmet medical needs. The successful closing of this PIPE financing will not only bolster Whitehawk’s financial position but may also enhance its ability to attract further investment and partnerships in the future.

Overall, this transaction reflects broader trends in the healthcare investment landscape, where institutional investors are increasingly looking to support innovative biotech firms. As competition intensifies within the oncology therapeutics sector, access to capital will be crucial for companies aiming to bring new therapies to market and achieve sustainable growth. Whitehawk’s PIPE financing is a strategic move that aligns with these market dynamics and positions the company for future success.